MX2022007553A - Formas solidas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazol o[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxeta n-3-il)piperazin-1-il]pent-2-enenitrilo. - Google Patents

Formas solidas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazol o[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxeta n-3-il)piperazin-1-il]pent-2-enenitrilo.

Info

Publication number
MX2022007553A
MX2022007553A MX2022007553A MX2022007553A MX2022007553A MX 2022007553 A MX2022007553 A MX 2022007553A MX 2022007553 A MX2022007553 A MX 2022007553A MX 2022007553 A MX2022007553 A MX 2022007553A MX 2022007553 A MX2022007553 A MX 2022007553A
Authority
MX
Mexico
Prior art keywords
solid forms
enenitrile
pent
piperazin
pyrazol
Prior art date
Application number
MX2022007553A
Other languages
English (en)
Inventor
Jiang Zhu
Mohammad Masjedizadeh
Pasit Phiasivongsa
Katherine Chu
Kolbot By
Original Assignee
Principia Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Principia Biopharma Inc filed Critical Principia Biopharma Inc
Publication of MX2022007553A publication Critical patent/MX2022007553A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Formas sólidas del compuesto (I): (ver Fórmula) se describen. También se describen composiciones farmacéuticas que los comprenden, métodos para tratar desórdenes y condiciones mediadas por actividad de BTK usando los mismos, y métodos para preparar el Compuesto (I) y formas cristalinas de este.
MX2022007553A 2019-12-20 2020-12-17 Formas solidas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazol o[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxeta n-3-il)piperazin-1-il]pent-2-enenitrilo. MX2022007553A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951958P 2019-12-20 2019-12-20
US202063122309P 2020-12-07 2020-12-07
PCT/US2020/065689 WO2021127231A1 (en) 2019-12-20 2020-12-17 Solid forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Publications (1)

Publication Number Publication Date
MX2022007553A true MX2022007553A (es) 2022-07-19

Family

ID=74186901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007553A MX2022007553A (es) 2019-12-20 2020-12-17 Formas solidas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazol o[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxeta n-3-il)piperazin-1-il]pent-2-enenitrilo.

Country Status (13)

Country Link
US (2) US11708370B2 (es)
EP (1) EP4076670A1 (es)
JP (1) JP2023507125A (es)
KR (1) KR20220119646A (es)
CN (1) CN115515687A (es)
AU (1) AU2020405096A1 (es)
BR (1) BR112022011516A2 (es)
CA (1) CA3162219A1 (es)
CO (1) CO2022008023A2 (es)
IL (1) IL293849A (es)
MX (1) MX2022007553A (es)
TW (1) TW202138371A (es)
WO (1) WO2021127231A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023244562A1 (en) 2022-06-14 2023-12-21 Principia Biopharma Inc. Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1- yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
PT2892900T (pt) 2012-09-10 2017-11-06 Principia Biopharma Inc Compostos de pirazolopirimidina como inibidores de cinase
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
CN110483521B (zh) * 2018-05-14 2022-06-07 杭州和正医药有限公司 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用
WO2022081512A1 (en) 2020-10-12 2022-04-21 Synubi Pharmaceuticals Llc Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
AU2020405096A1 (en) 2022-08-11
US11708370B2 (en) 2023-07-25
TW202138371A (zh) 2021-10-16
KR20220119646A (ko) 2022-08-30
WO2021127231A1 (en) 2021-06-24
CO2022008023A2 (es) 2022-09-09
US20210198264A1 (en) 2021-07-01
US20230399330A1 (en) 2023-12-14
EP4076670A1 (en) 2022-10-26
CN115515687A (zh) 2022-12-23
BR112022011516A2 (pt) 2022-08-23
JP2023507125A (ja) 2023-02-21
CA3162219A1 (en) 2021-06-24
IL293849A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MX2021000925A (es) Inhibidores de inflamasoma nlrp3.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
TW200621748A (en) Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
MX2022001181A (es) Inhibidores de kif18a.
SG10201902206QA (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
MX2016010754A (es) Sales y forma solida de un inhibidor btk.
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
PT1853232E (pt) Forma cristalina estável de mesilato de bifeprunox, suas formas de dosagem e métodos para a sua utilização
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
BR112021026531A2 (pt) Composto, composição farmacêutica, e, método para prevenir ou tratar uma doença mediada pela tirosina cinase 2
BR112021023054A2 (pt) Formas cristalinas de um inibidor de btk
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
MX2023011065A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
MX2022007553A (es) Formas solidas de 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)pirazol o[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4-metil-4-[4-(oxeta n-3-il)piperazin-1-il]pent-2-enenitrilo.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
ZA202206266B (en) Pd-l1 antagonist compound
WO2020197059A3 (ko) 엽산, 엽산 유도체, 또는 엽산 저해제를 이용한 줄기세포의 연골세포로의 분화 유도 방법
MX2021008712A (es) Derivados heterociclicos.